Testing GT801 for severe autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have one of these autoimmune diseases: lupus, myositis, scleroderma, ANCA vasculitis, or Sjogren's syndrome.
- Your disease must be moderate to severe and not well-controlled after at least 6 months of standard treatments.
- You must have certain lab results (like blood counts, kidney and liver function) within safe ranges.
- You must not have had CAR-T therapy before, and must not have other serious health issues like heart disease, active infections, or recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
Hear when a new Moderate to Severe Refractory Autoimmune Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.